RxDoctor Payments DataLook up a doctor →

Catherine Papasakelariou, MD

Dermatology · Houston, TXNPI 1679890313

Payments from drug & device makers

$289,485in general payments, 2019–2025

Across 1,134 payments — averaging $255.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$129K
  • Incyte Corporation$65K
  • Amgen$33K
  • Dermavant Sciences, Inc.$26K
  • Bristol Myers Squibb$20K
  • AbbVie$4K
  • plus $13K from 32 others

What the payments were for

  • Consulting fees$13,3385%
  • Speaking & faculty fees$228,80179%
  • Travel & lodging$14,8155%
  • Food & beverage$32,27111%
  • Education$2600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$289,485 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$113,932
Medicare patients
497
Services billed
2,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole14$13,438
Doxycycline Hyclate66$2,287
Ketoconazole119$1,982
Fluorouracil27$1,740
Fluocinonide28$1,113
Mupirocin102$785
Triamcinolone Acetonide83$754
Clobetasol Propionate13$640
Hydrocortisone85$526
Clindamycin Phosphate12$386
Hydroxyzine Hcl19$279
Ciclopirox11$198
ValacyclovirValacyclovir Hcl20$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$349$13,43814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →